We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Manipulating MicroRNA Levels May Return Cancer Cells to Normalcy

By LabMedica International staff writers
Posted on 07 Sep 2015
A possible approach for inducing cancer cells to revert to a precancerous state is based on the protein PLEKHA7 (Pleckstrin homology domain-containing family A member 7), which regulates the levels of select microRNAs (miRNAs) to suppress expression of cell transforming factors.

Investigators at the Mayo Clinic (Jacksonville, FL, USA) had been trying to explain why two proteins, E-cadherin and p120 catenin (catenin [cadherin-associated protein], delta 1 or p120) sometimes seemed to suppress cancer formation and at other times seemed to promote it.

Cadherins (named for “calcium-dependent adhesion”) are a class of type-1 transmembrane proteins. They play important roles in cell adhesion, ensuring that cells within tissues are bound together. They are dependent on calcium (Ca2+) ions to function, hence their name. Loss of E-cadherin function or expression has been implicated in cancer progression and metastasis. E-cadherin downregulation decreases the strength of cellular adhesion within a tissue, resulting in an increase in cellular motility. This in turn may allow cancer cells to cross the basement membrane and invade surrounding tissues.

The gene for p120 encodes a member of the Armadillo protein family, which function in adhesion between cells and signal transduction.

The investigators reported in the August 24, 2015, online edition of the journal Nature Cell Biology that PLEKHA7 recruited the so-called "microprocessor complex" (association of DROSHA and DGCR8 proteins) to a growth-inhibiting site (apical zonula adherens) in epithelial cells instead of sites at basolateral areas of cell–cell contact. If the microprocessor complex was recruited to a basolateral area instead of to the apical zonula adherens, miRNA regulation was disrupted, causing tumor growth. Restoring normal miRNA levels in tumor cells reversed that aberrant cell growth.

"We believe that loss of the apical PLEKHA7-microprocessor complex is an early and somewhat universal event in cancer," said senior author Dr. Panos Anastasiadis, chairman of the department of cancer biology at the Mayo Clinic. "In the vast majority of human tumor samples we examined, this apical structure is absent, although E-cadherin and p120 are still present. This produces the equivalent of a speeding car that has a lot of gas (the bad p120) and no brakes (the PLEKHA7-microprocessor complex). By administering the affected miRNAs in cancer cells to restore their normal levels, we should be able to reestablish the brakes and restore normal cell function. Initial experiments in some aggressive types of cancer are indeed very promising."

Related Links:

Mayo Clinic


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Urine Analyzer
respons® UDS100
Gold Member
Serum Indices Control
Acusera Serum Indices Control

Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more